↓ Skip to main content

Alemtuzumab for patients with chronic lymphocytic leukaemia

Overview of attention for article published in Cochrane database of systematic reviews, February 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
2 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
112 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Alemtuzumab for patients with chronic lymphocytic leukaemia
Published in
Cochrane database of systematic reviews, February 2012
DOI 10.1002/14651858.cd008078.pub2
Pubmed ID
Authors

Nicole Skoetz, Kathrin Bauer, Thomas Elter, Ina Monsef, Verena Roloff, Michael Hallek, Andreas Engert

Abstract

Chronic lymphocytic leukaemia (CLL) accounts for 25% of all leukaemias and is the most common lymphoid malignancy in Western countries. Standard treatment  includes mono- or poly-chemotherapies. Nowadays, monoclonal antibodies are added, especially alemtuzumab and rituximab. However, the impact of these agents remains unclear, as there are hints of an increased risk of severe infections.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 112 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Mexico 1 <1%
United States 1 <1%
France 1 <1%
Unknown 109 97%

Demographic breakdown

Readers by professional status Count As %
Student > Master 18 16%
Student > Bachelor 15 13%
Researcher 14 13%
Other 13 12%
Student > Postgraduate 11 10%
Other 26 23%
Unknown 15 13%
Readers by discipline Count As %
Medicine and Dentistry 46 41%
Agricultural and Biological Sciences 12 11%
Nursing and Health Professions 7 6%
Biochemistry, Genetics and Molecular Biology 5 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 4%
Other 16 14%
Unknown 22 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 May 2019.
All research outputs
#9,324,862
of 14,780,221 outputs
Outputs from Cochrane database of systematic reviews
#9,378
of 11,052 outputs
Outputs of similar age
#69,026
of 121,409 outputs
Outputs of similar age from Cochrane database of systematic reviews
#101
of 124 outputs
Altmetric has tracked 14,780,221 research outputs across all sources so far. This one is in the 24th percentile – i.e., 24% of other outputs scored the same or lower than it.
So far Altmetric has tracked 11,052 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 22.5. This one is in the 10th percentile – i.e., 10% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 121,409 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 124 others from the same source and published within six weeks on either side of this one. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.